Company Encyclopedia
View More
name
Rein Therapeutics
RNTX.US
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis.
1.936 T
RNTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Friday's After-Market Session

    During Friday's after-market session, several health care stocks experienced price changes. Gainers included Milestone Scientific, Streamex, GRI Bio, Intensity Therapeutics, Can Fite Biofarma, and SciSparc, with increases ranging from 3.86% to 4.7%. Losers included BioAtla, Nexalin Technology, Greenwich LifeSciences, Aspire Biopharma Holdings, Anebulo Pharmaceuticals, and Rein Therapeutics, with declines ranging from 3.4% to 6.2%.

    benzinga_article·
    US
    ASBP
    +11.34%
    US
    GRI
    -14.55%
    US
    RNTX
    -6.06%
    benzinga_article·
    US
    ASBP
    +11.34%
    US
    GRI
    -14.55%
    US
    RNTX
    -6.06%

    Owner Voss Capital LP Buys 104,183 ($127.6K) Of Rein Therapeutics Inc [RNTX]

    Voss Capital LP Beneficial Owner of Rein Therapeutics Inc [RNTX] filed a Form 4 on November 18, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/14/25TransactionPurchaseShares104,183Price$1.22Value$127,593Ending Holdings: 1,426,441 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    RNTX
    -6.06%
    Reuters·
    US
    RNTX
    -6.06%

    Voss Capital Reports Acquisition of Rein Therapeutics Common Shares

    Voss Capital, LP, and associated entities reported the acquisition of common shares of Rein Therapeutics Inc. as beneficial owners. The filing includes other beneficial owners and can be accessed via EDGAR. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    RNTX
    -6.06%
    Reuters·
    US
    RNTX
    -6.06%

    Rein Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RNTX
    -6.06%
    LB filings·
    US
    RNTX
    -6.06%

    Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments

    Analyst Brandon Folkes from H.C. Wainwright has reiterated a Buy rating on Rein Therapeutics, maintaining a price target of $10.00. This follows the FDA's clearance to lift the clinical hold on the Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, allowing U.S. trial enrollment to resume. The FDA's action suggests the market had undervalued RNTX, despite its strong scientific foundation. Brookline Capital Markets also upgraded the stock to a Buy with a $6.00 price target, highlighting LTI-03's dual mechanism and promising early data.

    Tip Ranks·
    US
    RNTX
    -6.06%
    Tip Ranks·
    US
    RNTX
    -6.06%
    © 2025 Longbridge｜Disclaimer